Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 8/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584643 | 0.91 | QDPR (0.45) | QDPRHTR2CSLC18A3SIGMAR1HTR6 | |
| SCHEMBL10282948 | 0.88 | PRKCI (0.47) | PRKCIPIK3CADYRK1A | |
| SCHEMBL5584682 | 0.87 | QDPR (0.47) | QDPRHTR2CSLC18A3SIGMAR1HTR6 | |
| SCHEMBL13061962 | 0.83 | PRKCI (0.44) | PRKCIPIK3CADYRK1A | |
| SCHEMBL5584981 | 0.81 | QDPR (0.51) | QDPRHTR2CSLC18A3SIGMAR1PIK3CD | |
| SCHEMBL5584893 | 0.81 | DYRK1A (0.42) | PRKCIDYRK1A | |
| SCHEMBL14046556 | 0.79 | QDPR (0.51) | QDPRPRKCIHTR6 | |
| SCHEMBL21788581 | 0.79 | HTR6 (0.43) | QDPRHTR2CSLC18A3SIGMAR1HTR6 | |
| SCHEMBL5584630 | 0.78 | QDPR (0.45) | QDPRHTR2CSLC18A3SIGMAR1HTR6 | |
| SCHEMBL23653045 | 0.78 | DYRK1A (0.43) | PRKCIDYRK1AL3MBTL1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| EP-0648767-B1 | Piperdine and piperazine derivatives which affect the C.N.S. | MERCK PATENT GMBH (DE) | 1997-05-28 | — | — | EP | disclosed |
| US-5532241-A | Piperidines and piperazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0459256-B1 | Oxazolidinones with CNS-depressant activity | MERCK PATENT GMBH (DE) | 1995-07-12 | — | — | EP | disclosed |
| EP-0648767-A1 | Piperdine and piperazine derivatives which affect the C.N.S. | MERCK PATENT GmbH (DE) | 1995-04-19 | — | — | EP | disclosed |
| US-5232931-A | OXAZOLIDINONES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-08-03 | — | — | US | disclosed |
| EP-0459256-A1 | Oxazolidinones with CNS-depressant activity | MERCK PATENT GmbH (DE) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | QDPR 66/4885HTR2C 2119/4885SLC18A3 1573/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | QDPR 66/4885HTR2C 2119/4885SLC18A3 1573/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | QDPR 214/4885HTR2C 9/4885SLC18A3 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.